Novartis AG ADR buy melinda
Start price
30.07.17
/
50%
€77.06
Target price
20.09.17
€77.57
Performance (%)
0.91%
End price
20.09.17
€77.76
Summary
This prediction ended on 20.09.17 with a price of €77.76. The BUY prediction by melinda for Novartis AG ADR closed nearly unchanged. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | -0.877% | -0.877% | 20.469% | 30.485% |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% | 65.292% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% | 97.467% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% | 39.755% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% | 61.093% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Zykadia (sNDA)
FDA Entscheidung über Zykadia als First-Line - Behandlung von Patienten mit Krebs der Lunge metastasierendem nicht-kleinzelligen (NSCLC) , deren Tumoren sind anaplastic lymphatische Kinase (ALK) - positiv
2017.08.23
FDA genehmigt den erweiterten Einsatz von Zykadia 26, Mai 2017